Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement

Nutrition and Cancer

Volumn 34, Issue 1, 1999, Pages 62-69

  Sun, Alexander S ^a   Ostadal, Oldrich ^b   Ryznar, Vaclav ^b   Dulik, Ivan ^a   Dusek, Jaroslav ^b   Vaclavik, Ales ^b   Yeh, Hsu Chong ^c   Hsu, Ching ^d   Bruckner, Howard W ^c   Fasy, Thomas M ^c  

^a Connecticut Inst Aging and Cancer ^*  (United States)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GLUCAN; BIOCHANIN A; GENISTEIN; ISOFLAVONE; LECTIN; PHYTIC ACID; PHYTOSTEROL; PROTEINASE INHIBITOR; SAPONIN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; SURVIVAL TIME; VEGETABLE;

EID: 0032815828     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC340109     Document Type: Article

References (67)

1. Parker, SL, Tong, T, Bolden, S, and Wingo, PA: Cancer statistics. CA Cancer J Clin 47, 5-27, 1997.
2. Western Europe unifying to tackle varied cancer problems. JNCI 84, 836-839, 1992.
3. Jabanzeb, M, and Ihde, DC: Role of adjuvant therapy in patients with surgically resected non-small cell lung cancer. Cancer Control 21, 467-473, 1994.
4. Shepherd, FA: Future directions in the treatment of non-small cell lung cancer. Semin Oncol 21, 48-62, 1994.
5. Mountain, CF: Lung cancer staging classification. Clin Chest Med 14, 43-53, 1993.
6. Chang, AY, Kim, K, Glick, J, Anderson, T, Karp, D, et al.: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. JNCI 85, 388-394, 1993.
7. Cangemi, V, Volpino, P, D'Andrea, N, Poupolo, M, Fabrizi S, et al.: Local and/or distant recurrences in T1-2/N0-1 non-small cell lung cancer. Eur J Cardiothorac Surg 9, 473-478, 1995.
8. Gauden, S, Ramsay, J, and Tripcony, L: The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 108, 1278-1282, 1995.
9. Torosian, MH, and Daly, JM: Nutritional support in the cancer-bearing host. Cancer 58, 1915-1929, 1986.
10. Evans, WK, Nixon, JM, Daly, JM, Ellenberg, SS, Gardner L, et al.: A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 5, 113-124, 1987.
11. Hartwell, JL: Plants used against cancer: a survey. Lloydia 30, 379-436, 1967; 31, 71-170, 1968; 32, 79-107, 153-205, 247-296, 1969; 33, 97-194, 288-392, 1970; 34, 103-160, 204-255, 310-360, 368-438, 1971.
12. Hartwell, JL: Plants used against cancer: a survey. Lloydia 30, 379-436, 1967; 31, 71-170, 1968; 32, 79-107, 153-205, 247-296, 1969; 33, 97-194, 288-392, 1970; 34, 103-160, 204-255, 310-360, 368-438, 1971.
13. Hartwell, JL: Plants used against cancer: a survey. Lloydia 30, 379-436, 1967; 31, 71-170, 1968; 32, 79-107, 153-205, 247-296, 1969; 33, 97-194, 288-392, 1970; 34, 103-160, 204-255, 310-360, 368-438, 1971.
14. Hartwell, JL: Plants used against cancer: a survey. Lloydia 30, 379-436, 1967; 31, 71-170, 1968; 32, 79-107, 153-205, 247-296, 1969; 33, 97-194, 288-392, 1970; 34, 103-160, 204-255, 310-360, 368-438, 1971.
15. Hartwell, JL: Plants used against cancer: a survey. Lloydia 30, 379-436, 1967; 31, 71-170, 1968; 32, 79-107, 153-205, 247-296, 1969; 33, 97-194, 288-392, 1970; 34, 103-160, 204-255, 310-360, 368-438, 1971.
16. Billings, PC, Newberne, PM, and Kennedy, AR: Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 11, 1083-1086, 1990.
17. Messadi, DV, Billings, PC, Shklar, G, and Kennedy, AR: Inhibition of oral carcinogenesis by a protease inhibitor. JNCI 76, 447-452, 1986.
18. Witschi, H, and Kennedy, AR: Modulation of lung tumor development in mice with the soybean-derived Bowman-Birk protease inhibitor. Carcinogenesis 10, 2275-2277, 1989.
19. Barnes, S, Grubbs, C, Setchell, KD, and Carlson, J: Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 347, 239-253, 1990.
20. Limtrakul, P, Suttajit, M, Semura, R, Shimada, K, and Yamamoto, S: Suppressive effect of soybean milk protein on experimentally induced skin tumor in mice. Life Sci 53, 1591-1596, 1993.
21. Yavelow, J, Collins, M, Birk, Y, Troll, W, and Kennedy, AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray-induced transformation in vitro. Proc Natl Acad Sci USA 82, 5395-5399, 1985.
22. Kennedy, AR, and Little, JB: Effects of protease inhibitor on radiation transformation in vitro. Cancer Res 41, 2103-2108, 1981.
23. Kennedy, AR, and Billings, PC: Anticarcinogenic actions of protease inhibitors. In Anticarcinogenesis and Radiation Protection. PA Cerutti, OF Nygaard, and MG Simic (eds). New York: Plenum, 1987, pp 285-295.
24. Evans, SM, van Winkle, T, Szuhaj, B, Michel, KE, and Kennedy, AR: Protection against metastasis of radiation-induced thymic lymphosarcoma and weight loss in C57B1/6NCr1BR mice by an autoclave-resistant factor present in soybeans. Radiat Res 132, 259-262, 1992.
25. Raicht, RF, Cohen, BI, Fazzini, EP, Sarwal, AN, and Takahashi, M: Protective effect of plant sterols against chemically induced colon tumors in rats. Cancer Res 40, 403-405, 1980.
26. Deschner, EE, Cohen, BI, and Raicht, RF: The kinetics of the protective effect of β-sitosterol against MNU-induced colonic neoplasia. J Cancer Res Clin Oncol 103, 49-54, 1982.
27. Maharaj, I, Froh, KJ, and Campbell, JB: Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. Can J Microbiol 32, 414-420, 1986.
28. Huang, HP, Chen, CF, Lin, WQ, Yang, GX, Song, JY, et al.: Antitumor activity of total saponins from Dolichos falactus. Klein Acta Pharmacol Sinica 3, 386, 1982.
29. Tokyda, H: Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate and teleocidin-B-induced Epstein-Barr virus by saponin and its related compounds. Cancer Lett 40, 309-317, 1988.
30. Fotsis, T, Pepper, M, Adlercreutz, H, Fleischmann, G, Hase, T, et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90, 2690-2694, 1993.
31. Peterson, G, and Barnes, S: Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22, 335-345, 1993.
32. Yanagihara, K, Ito, A, Toge, T, and Numoto, M: Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 53, 5815-5821, 1993.
33. Shamsuddin, AM: Inositol phosphates have novel anticancer function. J Nutr 125, 725S-732S, 1995.
34. Baten, A, Ullah, A, Tomazic, VJ, and Shamsuddin, AM: Inositol phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression. Carcinogenesis 10, 1595-1598, 1989.
35. Shamsuddin, AM, Elsayed, AM, and Ullah, A: Suppression of large intestinal cancer in F344 rats by inositol hexaphosphate. Carcinogenesis 9, 577-580, 1988.
36. Shamsuddin, AM, and Ullah, A: Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 10, 625-626, 1989.
37. Shamsuddin, AM, Ullah, A, and Chakravarthy, AK: Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. Carcinogenesis 10, 1461-1463, 1989.
38. Shamsuddin, A, Baten, A, and Lalwani, ND: Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. Cancer Lett 64, 195-202, 1992.
39. Chihara, G, Maeda, Y, Hamuro, J, Sasaki, T, and Fukuoka, F: Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) Sing. Nature 222, 687-688, 1969.
40. Maeda, YY, and Chihara, G: Lentinan, a new immuno-accelerator of cell-mediated responses. Nature 229, 634, 1971.
41. Maeda, YY, and Chihara, G: The effects of neonatal thymectomy on the antitumor activity of lentinan, carboxymethylpachymaran, and zymosan, and their effects on various immune responses. Int J Cancer 11, 153-161, 1973.
42. Hamuro, J, Maeda, Y, Fukuoka, F, and Chihara, G: Antitumor polysaccharides, lentinan and pachymaran as immunopotentiators. Mushroom Science. IX (Part I). Proc 9th Int Sci Congr Cultivation Edible Fungi, Tokyo, 1974, pp 477-487.
43. Chihara, G, Hamuro, J, Maeda, YY, Shiio, T, Suga, T, et al.: Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator; an overview. Cancer Detect Prev Suppl 1, 423-443, 1987.
44. Arinaga, S, Karimine, N, Takamuku, K, Nanbara, S, Nagamatsu, M, et al.: Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma, Int J Immunopharmacol 14, 43-47, 1992.
45. Arinaga, S, Karimine, N, Takamuku, KK, Nanbara, S, Inoue, H, et al.: Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14, 535-539, 1992.
46. Hamuro, J, Rollinghoff, M, and Wagner, H: β-(1-3)-Glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res 38, 3080-3085, 1978.
47. Hamuro, J, Wagner, H, and Rollinghoff, M: β-(1-3)-Glucans as a probe for T cell-specific immune adjuvants. II. Enhanced in vitro generation of cytotoxic T lymphocytes. Cell Immunol 38, 328-335, 1978.
48. Hamuro, J, Rollinghoff, M, and Wagner, H: Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the β(1-3) glucan-type lentinan and its analogues. Immunology 39, 551-559, 1980.
49. Hashim, OH, Gendeh, GS, and Jaafar, MI: Lectin extracts of champedak seeds demonstrate selective stimulation of T lymphocyte proliferation. Biochem Int 27, 139-143, 1992.
50. Licastro, F, Morini, MC, Kretz, O, Dirheimer, G, Creppy, EE, et al.: Mitogenic activity and immunological properties of bolesatine, a lectin isolated from the mushroom Boletus satanas Lenz. Int J Biochem 25, 789-792, 1993.
51. Ames, BN, Gold, LS, and Willett, WC: The causes and prevention of cancer. Proc Natl Acad Sci USA. 92, 5258-5265, 1995.
52. Bailar, JC, III, and Heather, LG: Cancer undefeated. N Engl J Med 336, 1569-1574, 1997.
53. Kamofsky, DA, Abelmann, WH, Craver, LF, and Burchenal, JH: The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1, 634-669, 1948.
54. Kaplan, EL, and Meier, P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53, 457-482, 1958.
55. Peto, R, and Peto, J: Asymptotically efficient rank in variant test procedures. J R Stat Soc A 135, 185-207, 1972.
56. Hollander, M, and Wolfe, DA: Nonparametric Statistical Methods. New York: Wiley, 1973.
57. Zelen, M: Theory and practice of clinical trials. In Cancer Medicisne, 4th ed, JF Holland, E Frei III, RC Bast, Jr, DW Kufe, and DL Morton (eds). Baltimore, MD: Weichselbaum Williams & Wilkins, 1997, pp 423-444.
58. Cassileth, BR, Walsh, WP, and Lusk, EJ: Psychosocial correlates of cancer survival: a subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol 6, 1753-1759, 1988.
59. O'Connell, JP, Kris, MG, Gralla, RJ, Groshen, S, Trust, A, et al.: Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4, 1604-1614, 1986.
60. Sculier, JP, Paesmans, M, Libert, P, Bureau, G, Dabouis, G, et al.: Long-term survival after chemotherapy containing platinum derivatives in patients with advanced unresectable non-small lung cancer. Eur J Cancer 30A, 1342-1347, 1994.
61. Hespanhol, V, Queiroga, H, Magalhaes, A, Santos, AR, Coelho, M, et al.: Survival predictors in advanced non-small cell lung cancer. Lung Cancer 13, 253-267, 1995.
62. Coates, A, and Forbes, J: Is chemotherapy for non-small cell lung cancer worthwhile? Lancet 342, 4, 1993.
63. Feld, R: Quality of life in patients with non-small cell lung cancer treated with chemotherapy. Eur J Cancer Clin Oncol 23, 357-359, 1987.
64. Sulitzeanu, D: Immunosuppressive factors in human cancer. Adv Cancer Res 60, 247-267, 1993.
65. Niehans, GA, Brunner, T, Frizelle, SP, Liston, JC, Salerno, CT, et al.: Human lung carcinomas express Fas ligand. Cancer Res 57, 1007-1012, 1997.
66. Smith, DR, Kunkel, SL, Standiford, TJ, Chensue, SW, Rolfe, MW, et al.: The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 143, 794-803, 1993.
67. Smith, DR, Kunkel, SL, Burdick, MD, Wilke, CA, Orringer, MB, et al.: Production of interleukin-10 by human bronchogenic carcinoma. Am J Pathol 145, 18-25, 1994.